



## Spasticity in the Medically Complex Child

Kavita Parikh, MD

Olga Morozova, MD

Melanie Anspacher, MD

Neha Shah, MD



# Spasticity





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

Describe the signs, symptoms and complications of spasticity

Identify the patient with spasticity that is not optimally managed

Summarize the different pharmacologic and non-pharmacologic treatment modalities

Plan a basic approach to managing spasticity in a patient  
Identify the role of the consultant (PM&R) in helping with management

Identify the patient with baclofen withdrawal and initiate management





# Spasticity





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenerivation

Summary

References & Resources

Spasticity =

**Motor Disorder**

*Velocity Dependent*





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources



Velocity  
dependent  
Stretch  
dependent

UMN signs  
Muscle  
over-activity





# Spasticity

## Upper Motor Neuron Syndrome

### Positive Symptoms

- Spasticity
- Clonus
- Flexor/extensor spasm
- Hyper-reflexia

### Negative Symptoms

- Weakness
- ↓ dexterity
- Paralysis
- Fatigability
- ↓ movement

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources





# Spasticity







Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

## Brain Injury

- traumatic brain injury, cerebral palsy, stroke, bacterial meningitis, encephalitis, tumor, MS

## Spinal Cord Injury

- tumor, infection, trauma, MS

## Neuromuscular

- ALS, Friederich ataxia

## Genetic disorders and degenerative diseases

- Sjogren-Larsson syndrome, Tay-Sachs disease, and Rett syndrome





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

## Cerebral Palsy :

- Disorders of movement and posture causing activity limitations
- Non-progressive disturbances of developing brain



Underlying lesion is static, but musculoskeletal pathology is progressive





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary


References & Resources

## Musculoskeletal Progression in Cerebral Palsy

**Static**  
**CNS Lesion**

**Progressive**  
**Musculoskeletal deformity**

Upper Motor Neuron Syndrome  
Spasticity and Weakness  
Failure of longitudinal muscle growth  
Fixed contracture  
Bony torsion  
Joint instability  
Joint dislocation  
Joint and bone degenerative changes



**Must repeatedly screen children for joint dislocation as they grow**





# Spasticity





# Spasticity

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

Motor Control

Bowel/Bladder

Skeletal & Skin

Self Esteem





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

## Muscle Tone

- Ashworth Scale
- Modified Ashworth Scale

Muscle reaction at different velocity of stretch

- Tardieu Scale

Range of Motion

Muscle Strength

Disability/Function

Overall Motor Function





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

Ashworth Scale	
Grade	Description
0	No increase in tone
1	Slight increase in tone giving a 'catch' when the limb is moved in the flexion or extension
2	More marked increase in tone, but limb is easily flexed
3	Considerable increase in tone, passive movement difficult
4	Limb rigid in flexion or extension





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

Modified Ashworth Scale	
Grade	Description
0	No increase in tone
1	Slight increase in tone - a catch and release at the end of the range of motion
1+	Slight increase in tone - catch, followed by minimal resistance in remainder of range
2	More marked increase in tone through most of range
3	Considerable increase in tone, passive movement difficult
4	Affcted parts rigid in flexion or extension







Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

## Tardieu Scale

V1: As slow as possible (minimizing stretch reflex)\*

V2: Speed of the limb segment falling under gravity\*\*

V3: As fast as possible (faster than the rate of the natural drop of the limb segment under gravity)\*\*

\*V1 measures passive range of motion (PROM)

\*\* V2 and V3 used to rate spasticity





# Spasticity





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

Observation of function

Identify movement disorder

Assess sensibility

Determine active and passive ROM

Evaluate spasticity, strength, and  
reflexes

Evaluate posture, gait, and balance





# Spasticity





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

## Treatment Plan ↔ Patient Goals

Impact Patient Function?

Impact Daily Care?





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

Decrease Tone

Increase range of motion

Improve fit and use of orthoses

Decrease contractures

Delay surgery

Improve position for care

Improve function

Decrease caregiver burden





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary


References & Resources

### Treatment Factors

- Drug formulation
- Drug Frequency
- Drug delivery
- Side effects
- Cost

### Disease Factors

- Generalized vs. Focal
- Comorbidities
- Chronicity
- Prognosis



### Patient Factors

- Patient and family motivation
- Availability of services and resources
- Compliance





# Spasticity

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications


Intrathecal Baclofen

Selective Rhizotomy

Chemodenerivation

Summary

References & Resources







Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy


Chemodenervation

Summary

References & Resources

## Spasticity Management Team

- Patient
- Caregiver
- Pediatrician
- Physiatrist (PMR)
- Neurologist
- Orthopedic surgeon
- Neurosurgeon
- Therapist : PT, OT, Speech
- Orthotist and Durable Medical Equipment provider
- Other: Social Work, Dietician, Education specialist



**As children age, they may be more likely to need orthoses and surgery.**





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

## What is the Role of the Physiatrist?

Function at home and in the community

Orthoses and therapeutic equipment

Altered muscle tone

Facilitating the ability of the child and family to set functional goals





# Spasticity

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

Development

Muscle Tone

Pain

Dysautonomia





# Spasticity





# Spasticity

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources





# Spasticity

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

Surgical and Pharmacologic Treatment

General

Oral Medications  
Intrathecal baclofen

Selective dorsal rhizotomy

Reversible

Chemo-denervation

Local corrective surgery

Permanent

Focal





# Spasticity

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications


Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources





# Spasticity







Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

Medication	Mechanism of Action	Most Common Side Effects
Baclofen	- Spinal cord - GABA B agonist	- Lowers seizure threshold
Benzodiazepines: Diazepam, clonazepam	- GABA A agonist - Spinal cord, brain	- Drooling
Tizanidine (Zanaflex)	- Alpha-2 agonist - Spinal cord, brain	- Hypotension - Hepatotoxicity
Dantrolene	- Calcium channel blocker - Muscle	- Hepatotoxicity
Trihexyphenidyl (Artane)	- Anticholinergic - Central muscarinic receptors	- Dry mouth





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

Medication	Initial Dose	Maximum per day	Doses/Day
Baclofen	2.5-5 mg x 2-3/day 0.6 mg/kg/d tid for <12 mo	40-90 mg (age dependant)	3-4
Diazepam	0.12-0.8mg/kg		3-4
Clonazepam	0.01-0.03 mg/kg/day	0.1-0.2 mg/kg/d	2-3
Tizanidine	2 mg/day	36 mg/day	2-3
Dantrolene	25 mg/day (0.5mg/kg daily)	12 mg/kg/day or 400 mg/day	2-4
Artane	1 mg/day	15 mg/day	2





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy


Chemodeneration

Summary

References & Resources

Sedation is one of the common side effects with all oral medications

To minimize potential sedation, always start low and titrate up slow



**Abrupt withdrawal can result in seizures**

**If NPO, can use IV Diazepam**





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration


Summary

References & Resources

## First Line: Oral Baclofen

### AVOID MEDICATION ERROR

- ✓ Concentration is variable
- ✓ 1 ml  $\neq$  1 mg



**When prescribing oral baclofen, the dose MUST be verified to avoid fatal medication errors!**





# Spasticity





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen


Selective Rhizotomy

Chemodeneration

Summary

References & Resources

**Intrathecal baclofen:  
50x response  
of oral  
baclofen**





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

## Who is a candidate?

Severe, generalized tone

Not successfully managed with oral  
medications

Improvement with test dose of intrathecal  
baclofen given via lumbar puncture





# Spasticity

Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

## PROS:

**GABA inhibition without side effects in the brain**

**Programmable to set best dose**

## CONS:

**Complications of device**

**High maintenance of pump**







Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

## Mechanical

- CSF leak
- Catheter malfunction
- Infection

## Medical

- Overdose
- Withdrawal





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenerivation

Summary

References & Resources

## Baclofen withdrawal

### Early signs:

- Pruritis
- Dysphoria
- Irritability
- Spasticity
- Tachycardia
- Fever
- Hypertension
- Respiratory Distress

### Late signs:

- Hyperthermia
- Seizures
- Rhabdomyolysis
- DIC
- Altered Mental Status
- Psychomotor agitation
- Respiratory Distress
- Multisystem Organ Failure

**Death**





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications


Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources





# Spasticity





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

## What is Selective Rhizotomy?

NERVES

Isolated

Targeted

Destroyed

Improved Spasticity





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

## Who is a Good Candidate?

Ages between 4 and 7 years

“Pure” spasticity

Ambulatory

Absence of fixed contractures

Cooperation with intensive therapy





# Spasticity

Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary



Copyright © [2001] Professional Postgraduate Services®. All rights reserved.





# Spasticity







Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

	Botulinum Toxin Type A	Phenol
Mechanism of Action	Selective motor denervation at the NM junction (presynaptic block of ACh release)	Non-selective chemical neurolysis in injected nerve
Onset	24-72 hours	< 1 hour
Duration	6-12 weeks (3-6 months functional outcome)	2-36 months
Side Effects	Weakness	Dysesthesia, skin necrosis
Pros	Easy to inject Limited dose of toxin	Low cost
Cons	Cost	Difficult to inject





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

## Advantages

- Temporary\*
- Minimally invasive
- Increase ROM
- Learn normal movement patterns
- Safely repeated
- Mimic surgical outcome
- Allows age-selective timing of surgery

## Disadvantages

- Temporary\*
- May decrease functional tone
- Total body dose of toxin limited (BTX-A)
- Cost (BTX-A)





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

## Who is a Good Candidate?

Focal increase in muscle tone

Absence of fixed contractures

Absence of bony/joint problems

No underlying bleeding disorder





Learning Objectives

Definition

Etiology & Pathophysiology

Impact of Spasticity & Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodenervation

Summary

References & Resources

## Timing of Botulinum Treatment

### Early Years

- May allow postponement, simplification, avoidance of surgery

### Later Years

- May provide pain relief, improved ease of care, functional goals





# Spasticity





Learning Objectives

Definition

Etiology &  
Pathophysiology

Impact of Spasticity &  
Outcome Measures

Exam Features

Treatment Plan

Treatment Options

Medications

Intrathecal Baclofen

Selective Rhizotomy

Chemodeneration

Summary

References & Resources

Spasticity = 1 component of the UMN syndrome

Spasticity = velocity dependent increased resistance to passive stretch

Underlying lesion is static, but musculoskeletal pathology is progressive

Treatment plan is not “one-size fits all”, but should be customized to patient’s goals

Most spasticity medications **CANNOT** be stopped abruptly. Should be weaned to avoid seizures, or switched to IV if patient is NPO.





# Spasticity

## Learning Objectives

## Definition

## Etiology & Pathophysiology

## Impact of Spasticity & Outcome Measures

## Exam Features

## Treatment Plan

## Treatment Options

## Medications

## Intrathecal Baclofen

## Selective Rhizotomy

## Chemodeneration

## Summary

## References & Resources

Bax, M., Goldstein, M., Rosenbaun, P., Leviton, A., Paneth, N., Dan, B., . . . Damiano, D. (2005). Proposed definition and classification of cerebral palsy, april 2005. *Developmental Medicine and Child Neurology*, 47(8), 571-576.

Brashear A and Mayer NH (editors). Spasticity and Other Forms of Muscle Overactivity in the Upper Motor Neuron Syndrome: Etiology, Evaluation, and Management, and the Role of Botulinum Toxin. We Move, 2008.

Brin, M. F., Albany, K., Alexander, D., Cava, T., Chambers, H. G., Childers, M. K., . . . Yablon, S. A. (1997). Spasticity, etiology, evaluation, management, and the role of botulinum toxin type A. *Muscle and Nerve*, 20(SUPPL. 6), S1-S223.

Elovic, E. P., Esquenazi, A., Alter, K. E., Lin, J. L., Alfaro, A., & Kaelin, D. L. (2009). Chemodeneration and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. *PM and R*, 1(9), 842-851.

Graham, H. K. (2001). Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy. *European Journal of Neurology*, 8(SUPPL. 5), 30-39.

Graham, H. K., Aoki, K. R., Autti-Rämö, I., Boyd, R. N., Delgado, M. R., Gaebler-Spira, D. J., . . . Wissel, J. (2000). Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. *Gait and Posture*, 11(1), 67-79.

Lance, J. W. (1980). The control of muscle tone, reflexes, and movement: Robert wartenberg lecture. *Neurology*, 30(12), 1303-1313.

Mayer, N. H., Esquenazi, A., & Childers, M. K. (1997). Common patterns of clinical motor dysfunction. *Muscle & Nerve.Supplement*, 6, S21-35.

Management of Spasticity in Children with Cerebral Palsy: An Integrated Approach. Jointly sponsored by Professional Postgraduate Services, a division of Physicians World/Thomson Healthcare, Secaucus, New Jersey. Release date September 2001.